Therapeutic options in the treatment of benign prostatic hyperplasia

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 213-223

  Sandhu, Jaspreet S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Benign prostatic hyperplasia; Prostatectomy; TURP

Indexed keywords

EID: 84882308849     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S4028     Document Type: Review

References (87)

1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479.
2. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's Urology. Philadelphia (PA): Saunders, 2002:1297-1336.
3. McConnell MD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557-563.
4. McConnell JD, Roehrborn CG, Bautista AM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2385-2396.
5. McConnell JD. Prostatic growth: New insights into hormonal regulation. Br J Urol. 1995;76(Suppl 1):5-10.
6. Imperato-McGinley J, Guerrero L, Gautieer T, et al. Steroid 5-alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213-1215.
7. Walsh PC, Madden JD, Harrod MJ, et al. Familial incomplete male pseudohermaphroditism type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974;291:944-949.
8. Shapiro E, Hartano V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immuno-enzymatic staining and color assisted image analysis. J Urol. 1992;147:1167.
9. Schwinn DA. Androgen receptors: Unique localization in human tissues. Adv Pharmacol. 1994;31:333-341.
10. Lepor H, Gup DI, Baumann M, et al. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1998;32:21-26.
11. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guidelines. No. 8., AHCPR Publication No. 94-0582. Rockville, MD: Agency for Health Care Policy and Research. Public Health Service, US Department of Health and Human Services, 1994.
12. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85-89.
13. Girman CJ, Panser LA, Chute CG, et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol. 1993;150:887-892.
14. Blute MI, Jacobsen SJ, Kaplan SA, et al. Evaluation and management of benign prostatic hyperplasia: proceedings of a thought leader conference held March 31, 2001. Urology. 2001;58:1-4.
15. Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481-487.
16. Rhodes T, Girman CJ, Jacobsen SJ, et al. Longitudinal prostate growth rates during 5 years in randomly selected men 40-79 years old. J Urol. 1999;161:1174-1179.
17. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology. 1999;54:662-669.
18. Hoffman RM, MacDonald R, Slaton JW, et al. Laser prostatectomy versus transuretheral resection for treating benign prostatic obstruction: a systematic review. J Urol. 2003;169:210-215.
19. Te AE, Malloy TR, Stein BS, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol. 2004;172:1404-1408.
20. Reich O, Bachmann A, Siebels M, et al. High power (80 W) potassiumtitanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol. 2005;173:158-160.
21. Sandhu JS, Ng C, Vanderbrink BA, et al. High-power potassiumtitanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology. 2004;64:1155-1159.
22. Tunuguntla HS, Evans CP. Minimally invasive therapies for benign prostatic hyperplasia. World J Urol. 2002;20:197-206.
23. Gup DI, Shapiro E, Bauman M, et al. Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate. 1989;15:105-114.
24. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebocontrolled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992;148:1467-1474.
25. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 1995;154:105-109.
26. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild-tomoderate essential hypertension: a double-blind, placebo controlled, dose-response multicenter study. J Urol. 1995;154:110-115.
27. AUA Practice Guideline Committee: AUA Guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment Recommendations. J Urol. 2003;170:530-547.
28. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998;51:892-900.
29. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170:498-502.
30. Martin DJ. Preclinical pharmacology of a1-adrenoreceptor antagonists. Eur Urol. 1999;36(suppl 1):35-41.
31. Lukacs B, Grange JC, Comet D, et al. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol. 2000;37:183-190.
32. Li X, Chen C, Singh SM, et al. The enzyme and inhibitors of 4-ene-oxosteroid 5 alpha-oxidoreductase. Steroids. 1995;60:430-441.
33. Rasmusson GH, Reynolds GF, Steinberg NG, et al. Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding. J Med Chem. 1986;29:2298-2315.
34. Gromley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327:1185-1191.
35. Beisland HO, Binkowitz B, Brekkan E, et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 1992;22:271-277.
36. Vaughan D, Imperato-Mcginley J, McConnell J, et al. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology. 2002;60:1040-1044.
37. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology. 1999;54:670-678.
38. Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 2001;57:1073-1077.
39. Matsumoto AM, Tenover L, McClung M, et al. The long term effect of specific type II 5-alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002;167:2105-2108.
40. Schafer W, Tammela TLJ, Barrett DM, et al. Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Urology. 1999;54:278-283.
41. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434-441.
42. Kearney MC, Bingham JB, Bergland R, et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol. 2002;167:2489-2491.
43. Pareek G, Shevchuk M, Armenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003;169:20-23.
44. Hagerty JA, Ginsberg PC, Harmon JD, et al. Pretreatment with finasteride decreases perioperative bleeding associated with transuretheral resection of the prostate. Urology. 2000;55:684-689.
45. Donahue JF, Sharma H, Abraham R. Transuretheral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol. 2002;168:2024-2026.
46. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533-539.
47. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) Trial. Urology. 2003;61:119-126.
48. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostate Symptoms (MTOPS) trial. Control Clin Trials. 2003;24:224-243.
49. Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003;61:791-796.
50. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology. 2003;61:354-358.
51. Walmsley K, Cjertsen CK, Kaplan SA. Medical management of BPH-an update. Campbell's Urology Updates. 2004;2:2.
52. Kaplan SA, Walmsley K, Te Ae. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273-2275.
53. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319-2328.
54. Rovner ES, Kreder K, Sussman DO, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008;180:1034-1041.
55. Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z. Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate Size. Eur Urol. 2009;55:472-481.
56. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51:1717-1723.
57. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53:1236-1244.
58. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401-1407.
59. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebocontrolled study. Urology. 2003;62:259-264.
60. Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology. 2009;73:90-94.
61. Lee R, Saini R, Kaplan SA, Te AE. A Review of Transurethral Microwave Thermotherapy. AUA Update Series. Lesson 28, Volume 26, 2007.
62. Hoffman RM, Monga M, Elliot SP, Macdonald R, Wilt TJ. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2007;4:CD004135.
63. Bouza C, López T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia. BMC Urol. 2006;6:14.
64. May F, Hartung R. Surgical atlas. Transurethral resection of the prostate. BJU Int. 2006;98:921-934.
65. Reich O, Gratzke C, Bachmann A, et al. Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180:246-249.
66. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)-incidence, management, and prevention. Eur Urol. 2006;50:969-979.
67. Wei JT, Calhoun EA, Jacobsen SJ. Benign Prostatic Hyperplasia. In: Litwin MS, Saigal CS, editors. Urologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Publishing Office, 2007; NIH Publication No. 07-5512 p. 43-70.
68. Kaplan SA, Te AE. Transurethral electrovaporization of the prostate: a novel method for treating men with benign prostatic hyperplasia. Urology. 1995;45:566-572.
69. Poulakis V, Dahm P, Witzsch U, Sutton AJ, Becht E. Transurethral electrovaporization vs transurethral resection for symptomatic prostatic obstruction: a meta-analysis. BJU Int. 2004;94:89-95.
70. Botto H, Lebret T, Barré P, Orsoni JL, Hervé JM, Lugagne PM. Electrovaporization of the prostate with the Gyrus device. J Endourol. 2001;15:313-316.
71. Ho HS, Yip SK, Lim KB, Fook S, Foo KT, Cheng CW. A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system. Eur Urol. 2007;52:517-522.
72. Gilleran JP, Thaly RK, Chernoff AM. Rapid communication: bipolar PlasmaKinetic transurethral resection of the prostate: reliable training vehicle for today's urology residents. J Endourol. 2006;20: 683-687.
73. Yang Q, Peters TJ, Donovan JL, Wilt TJ, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2001;165:1526-1532.
74. Cowles RS, Kabalin JN, Childs S, et al. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology. 1995;46:155-160.
75. Pypno W, Husiatynski W. Treatment of a benign prostatic hyperplasia by Nd:YAG laser-own experience. Eur Urol. 2000;38:194-198.
76. Gilling PJ, Cass CB, Cresswell MD, Malcolm AR, Fraundorfer MR. The use of the holmium laser in the treatment of benign prostatic hyperplasia. J Endourol. 1996;10:459-461.
77. Tan AH, Gilling PJ, Kennett KM, Fletcher H, Fraundorfer MR. Long-term results of high-power holmium laser vaporization (ablation) of the prostate. BJU Int. 2003;92:707-709.
78. Fraundorfer MR, Gilling PJ. Holmium:YAG laser enucleation of the prostate combined with mechanical morcellation: preliminary results. Eur Urol. 1998;33:69-72.
79. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate, and possible impact of the learning curve. Eur Urol. 2007;52:1465-1471.
80. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol. 2008;53:160-166.
81. Malek RS, Barrett DM, Kuntzman RS. High-power potassiumtitanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology. 1998;51:254-256.
82. Te AE, Malloy TR, Stein BS, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol. 2004;172:1404-1408.
83. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology. 2004;64:1155-1159.
84. Fu WJ, Hong BF, Wang XX, et al. Evaluation of greenlight photoselective vaporization of the prostate for the treatment of high-risk patients with benign prostatic hyperplasia. Asian J Androl. 2006;8:367-371.
85. Ruszat R, Wyler S, Forster T, et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol. 2007;51:1031-1038.
86. Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol. 2008;180:241-245.
87. Sandhu JS, Te AE. Open Prostatectomy. Atlas of Urology Clinics. 2002;10:17-25.